Compare LIDR & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIDR | AGEN |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.0M | 126.2M |
| IPO Year | N/A | 2000 |
| Metric | LIDR | AGEN |
|---|---|---|
| Price | $2.00 | $3.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $14.50 |
| AVG Volume (30 Days) | ★ 1.0M | 908.8K |
| Earning Date | 02-19-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $182,000.00 | ★ $106,829,000.00 |
| Revenue This Year | $9.07 | $23.68 |
| Revenue Next Year | $2,660.98 | $23.17 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.49 | $1.38 |
| 52 Week High | $6.44 | $7.34 |
| Indicator | LIDR | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 41.83 | 40.39 |
| Support Level | $1.91 | $3.12 |
| Resistance Level | $2.15 | $3.55 |
| Average True Range (ATR) | 0.11 | 0.38 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 22.89 | 6.57 |
AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).